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Chemical and physico-chemical properties as well as physiological functions of major mammalian ether-linked glycerolipids, including
plasmalogens were reviewed. Their chemical structures were described and their effect on membrane fluidity and membrane fusion discussed. The
recent generation of mouse models with ether lipid deficiency offered the possibility to study ether lipid and particularly plasmalogen functions in
vivo. Ether lipid-deficient mice revealed severe phenotypic alterations, including arrest of spermatogenesis, development of cataract and defects in
central nervous system myelination. In several cell culture systems lack of plasmalogens impaired intracellular cholesterol distribution affecting
plasma membrane functions and structural changes of ER and Golgi cisternae. Based on these phenotypic anomalies that were accurately
described conclusions were drawn on putative functions of plasmalogens. These functions were related to cell–cell or cell–extracellular matrix
interactions, formation of lipid raft microdomains and intracellular cholesterol homeostasis. There are several human disorders, such as Zellweger
syndrome, rhizomelic chondrodysplasia punctata, Alzheimer’s disease, Down syndrome, and Niemann–Pick type C disease that are distinguished
by altered tissue plasmalogen concentrations. The role plasmalogens might play in the pathology of these disorders is discussed.
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Ether-linked glycerolipids are widely distributed in nature
serving important structural and functional aspects of biological
membranes. They are found in bacteria, primitive protozoa,
fungi and higher plants and are present in mammals including
men. In mammals synthesis of the ether bond requires theAbbreviations: AAPH, 2,2′-azobis-(2-amidinopropane HCl); Aβ, β amy-
loid; AD, Alzheimer’s disease; ADAPS, alkyldihydroxyacetonephosphate
synthase; BACE, beta-site amyloid precursor protein cleaving enzyme; CDR,
clinical dementia ratings; CGT, UDP-galactose:ceramide galactosyltransferase;
CNS, central nervous system; CST, cerebroside sulfotransferase; DHA,
docosahexaenoic acid; DHAPAT, dihydroxyacetonephosphate acyltransferase;
DS, Down syndrome; FGSLs, fucosylated glycosphingolipids; GPI, glycosyl-
phosphatidylinositol; LRMs, lipid raft microdomains; NPC, Niemann–Pick type
C disease; OMgp, oligodendrocyte myelin glycoprotein; PAF, platelet-activating
factor; PTS, peroxisomal targeting signal; PPAR, peroxisome proliferator-
activated receptor; RCDP, rhizomelic chondrodysplasia punctata; ROS, reactive
oxygen species; SGalAAG, 1-O-alkyl-2-O-acyl-3-O-β-D-(3′-sulfo)galactosyl-
sn-glycerol; SOD, superoxide dismutase; ZS, Zellweger syndrome
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ferase (DHAPAT) and alkyldihydroxyacetonephosphate syn-
thase (ADAPS) [1]. Accordingly, plasmalogen levels are
considerably reduced in disorders based on defects in peroxi-
some assembly, such as the cerebro-hepato-renal (Zellweger)
syndrome (ZS) and rhizomelic chondrodysplasia punctata
(RCDP) [2–4]. RCDP type 2 and type 3 are both distinguished
by an isolated defect in ether lipid biosynthesis. The severe
pathology observed in these patients indicates the physiological
importance of ether lipids for normal human life. Althoughmuch
has been learned about ether lipid functions within the last
decade [2,5–8], it seems that we are still far away from a
comprehensive understanding of their physiological role.
In this review we mainly focus on mammalian ether lipids
particularly plasmalogens, since they represent the major
constituents in most tissues and the phenotypes connected
with impaired ether lipids are mainly caused by impaired
plasmalogen functions. However, we also consider the
particular situation in testis where both ether phospholipids
and seminolipid, a sulfogalactosyl alkylacylglycerol, contribute
to the phenotype of ether lipid deficiency. First, we will briefly
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biological functions so far as they were currently discussed.
Subsequently, we will focus on recent studies dealing with the
phenotypic changes seen in ether lipid-deficient mouse models
primarily the model based on isolated DHAPAT deficiency
[9,10]. In this model DHAPAT, the key enzyme in ether lipid
biosynthesis, is eliminated by targeted deletion resulting in the
complete absence of ether lipids. Major phenotypes observed in
these animals are described representing the basis for a
discussion of ether lipid functions in mammalian cell types
and organ systems.
2. Chemical aspects of mammalian ether lipids
2.1. Structure of ether lipids
The major constituents of the class of mammalian ether
phospholipids contain a single alkyl chain at the sn-1 position
linked to the glycerol backbone via an ether bond. Although
species with phosphoinositol or phosphoserine as a head group
have been described, the most abundant species belong to the
class of glycerophosphoethanolamine and glycerophosphocho-
line phospholipids [8]. Among these ether-bonded glyceropho-
spholipids those bearing an enol ether (vinyl ether) are called
plasmalogens and are by far the most abundant molecules in
mammalian tissues. According to a widely used nomenclature,
these plasmalogens are called plasmenylethanolamines and
plasmenylcholines, whereas their saturated counterparts are
called plasmanylethanolamines and plasmanylcholines (Fig. 1A
and B). The alkyl chains at the sn-1 position of plasmalogens
usually have chain lengths of C16 or C18 and the vinyl ether
double bond represents the cis-isomer. At the sn-2 position
plasmalogens preferably contain a long chain polyunsaturated
fatty acid both of the n-6 or n-3 class. In that sense platelet-
activating factor (PAF) bearing an acetyl residue at the sn-2
position is exceptional among the ether lipids (Fig. 1C). Recent
studies in mice carrying the targeted deletion of the PAF receptor
provided evidence for a beneficial attenuation of symptoms in
chemical lung injury, bronchial asthma, sponge-induced subcu-
taneous granuloma formation and folic acid-induced renal
inflammation mediated by infiltrating inflammatory cells [11].
In this review we will not further discuss PAF and its biological
functions. For this the reader is referred to a number of recent
publications [12–14].
Understanding the phenotypic changes seen in the
DHAPAT-deficient mouse model requires consideration of
two other ether-bonded lipid species, seminolipid (Fig. 1D)
and the glycosylphosphatidylinositol (GPI)-anchor of GPI-
anchored proteins that in mammalian tissues frequently
contain a 1-O-alkyl-2-O-acyl-sn-2-glycerol residue within the
GPI anchor moiety (Fig. 1E). Seminolipid is an 1-O-alkyl-2-
O-acyl-3-O-β-D-(3′-sulfo)galactosyl-sn-glycerol (SGalAAG)
that predominantly occurs in testes, but may also be present
in brain [15]. Interestingly, in brain the relative molar
concentrations of the diacyl and alkylacyl types of sulfoga-
lactosylglycerols change with age. Both types predominate in
the myelin fraction, the alkylacyl form still increasing inconcentration after the age of 22days, thus being the more
stable component of myelin.
GPI-anchoring of proteins is a posttranslational modification
that occurs in the ER and attaches proteins to the luminal side of
the membrane. Thus, following vectorial transport to the plasma
membrane GPI-anchored proteins are exposed at the extracel-
lular site of the plasma membrane. As shown in Fig. 1G the core
structure of the GPI-anchor consists of phosphatidylinositol
containing either diacyl- or 1-alkyl-2-acyl glycerol in addition
to glucosamine, trimannoside and phosphoethanolamine. The
latter provides the link to the C-terminus of the GPI-anchored
ectoprotein.
2.2. Chemistry of the plasmalogen-specific vinyl ether bond
Plasmalogens are distinguished by two characteristic
chemical reactivities. Firstly, their vinyl ether group is acid
labile and secondly, plasmalogens are classified as efficient in
vitro antioxidants being targets of a variety of oxidants, such as
singlet oxygen, peroxy radicals and metal ions.
The mechanism of the acid-catalyzed hydrolysis of general
vinyl ethers as model compounds of plasmalogens has been
investigated in detail [16]. The reaction proceeds in several
steps. The first one consisting in the addition of a proton to the
double bond is considered to be rate limiting. Once formed, the
carbonium ion is rapidly converted to the α-hydroxy-compound
that in the third step easily splits into aldehyde and alcohol.
Lysoplasmenylcholine is somewhat more rapidly hydrolyzed
than lysoplasmenylethanolamine and the cis-oriented double
bond, as it is present in natural plasmalogens, is much more
reactive than the corresponding trans-double bond.
There is a long lasting discussion on the antioxidative
character of plasmalogens. Within the last decade a large
number of articles appeared dealing with various aspects of the
antioxidative activity of plasmalogens. Again their vinyl ether
bond is target of oxidative attack by reactive oxygen species
(ROS), e.g. singlet oxygen, superoxide anion, hydrogen
peroxide and peroxy radicals. Metal ion-catalyzed reactions
particularly Fe3+/Fe2+ may strongly support these reactions.
The most important aspects of the scavanger functions of
plasmalogens are briefly summarized, as they might be essential
for understanding plasmalogen functions.
The reactions of olefins, unsaturated hydrocarbons, e.g. sub-
stituted acetylenes, ketenes or allenes, with singlet oxygen have
been thoroughly reviewed and may followmechanisms of either
1,2 addition forming dioxethanes or 1,3 addition on olefins
containing at least one allylic hydrogen [17]. Upon decompo-
sition dioxethanes readily cleave into two carbonyl-containing
fragments, whereas 1,3 addition yields allylic hydroperoxides
including a shift of the double bond to the adjacent carbon
atoms. The oxidation of vinyl ethers with hydrogen peroxide
in aqueous solution and trace amounts of catalysts was shown
to predominantly yield a mixture of α-hydroxyaldehydes and
α-hydroxyketones together with aldehydes derived from the
cleavage of the vinyl ether bond [18]. Using ethyl hexadec-1-
enyl ether as plasmalogen model and air oxygen as the oxidant,
disappearance of the vinyl ether and concomitant generation of
Fig. 1. Structure of major mammalian ether-linked membrane lipids. (A) plasmenylethanolamine (1-O-hexadecenyl-2-oleoyl-sn-glycerophosphoethanolamine,
phosphatidylethanolamine plasmalogen); (B) plasmanylethanolamine (1-O-hexadecyl-2-oleoyl-sn-glycerophosphoethanolamine); (C) platelet-activating factor
(PAF, 1-O-hexadecyl-2-acetyl-sn-glycerophosphocholine); (D) seminolipid (1-O-hexadecyl-2-oleoyl-3-O-β-D-(3′-sulfo)galactopyranosyl-sn-glycerol); (E) typical
glycosylphosphatidyl (GPI) anchor containing an ether-linked alkyl chain.
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demonstrated that alk-1-enyl ether underwent slow but
measurable oxidation. However, in the presence of polyun-
saturated compounds, such as linoleate or linolenate, disap-
pearance of the vinyl ether was greatly accelerated proceeding
at a rate comparable to that of the polyunsaturated compound
itself. These data suggest that the oxidation products of the
polyunsaturates attack the vinyl ether rather than the vinyl
ether protects the unsaturates from oxidation. Considering thefact that plasmalogens frequently have esterified polyunsatu-
rated fatty acids, preferably arachidonic acid, to the sn-2
hydroxyl group of the glycerol, these results might be
important discussing the antioxidative function of plasmalo-
gens. Other studies using 2,2′-azobis-(2-amidinopropane HCl)
(AAPH), a water-soluble peroxyl radical generator, also
reported the slow rate of oxidation of lysoplasmenylethano-
lamine and a delayed oxidative degradation of sn-2 arachido-
noyl diacyl glycerolipids by the presence of plasmalogens
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generated oxidation processes [20].
More recent studies on the oxidation of model glyceropho-
spholipids including arachidonate-containing plasmenylcholine
utilizing different strategies of oxidation, e.g. t-butylhydroper-
oxide, hydrogen peroxide/Cu2+, hydrogen peroxide/Fe2+ or
AAPH noted (i) qualitative and quantitative differences in the
oxidation products dependent on the mechanism of free radical
oxidation, (ii) carbon-5 of the arachidonate as the major site of
primary oxidation, (iii) plasmalogens themselves not to stop
oxidative events, although they form peroxidized products more
rapidly than their corresponding plasmanyl and diacyl glycer-
ophosphocholines and (iv) the peroxidation mechanism of
plasmalogens intimately involves the oxidation of the arachi-
donate. Thus, attack of plasmalogens by oxidants always is
distinguished by an intramolecular competition between the
double bonds of the vinyl ether and the polyunsaturated fatty
acid [21–28].
The major products and fragments generated by the
oxidation of plasmalogens are eicosatetraenoic acid hydroxy-
lated at the 5 (most abundant), 8, 9, 11, 12 and 15 position of
the arachidonic acid. In addition 5,12-dihydroxylated eicosa-
tetraenoic acid, 2-monoacylglycerophosphoethanolamine, pen-
tadecanol, formic acid, α-hydroxyaldehydes of various chain
lengths derived from plasmalogen epoxides, 1-formyl-2-
arachidonoyl glycerophospholipid and lysophospholipid were
identified [22–28]. Among the oxidation products many
aldehydic compounds were detected. Malondialdehyde a
common decomposition product of peroxides derived from
polyunsaturated fatty acids is frequently used to monitor lipid
peroxidation in biological material. Thiobarbituric acid reacts
with some specificity with malondialdehyde and thus,
thiobarbituric acid-reactive substances expressed in malon-
dialdehyde equivalents are a convenient measure to express
lipid peroxidation [29]. ROS have also been postulated to
contribute to aging-related alterations. This free radical theory
of aging was recently tested in senescence-accelerated mice
showing abnormal aging characteristics [30]. However, no
change was noted in brain plasmalogen concentrations and
aldehyde and α-hydroxyaldehyde levels were unaltered in
these mice compared with age-matched controls and remained
constant during aging [31]. More recently, the isoprostanes,
products of arachidonic acid oxidation, were found to be
accurate markers of lipid peroxidation in animal models of
oxidative stress illuminating oxidant injury in association with
a number of human diseases [32].
Strongest indication for a role of plasmalogens as endoge-
nous antioxidants came from experiments with pyrene-labeled
fatty acids, 12-(1′-pyrene) dodecanoic acid, fed to plasmalogen-
deficient CHO cells with otherwise normal peroxisomal
functions. ROS were generated by long-wavelength UV light
(>300nm) irradiation and were shown to be more cytotoxic in
mutant cells than in controls. Using mutant variants of a murine
macrophage cell line or mutant human fibroblast lines from
patients with peroxisomal disorders, evidence was provided for
the vinyl ether bond to function as the crucial element in this
activity protecting against ROS [8,33,34].2.3. Effect of plasmalogens on membrane fluidity
Model membranes composed of plasmanyl- and plasmeny-
lethanolamines were shown to exhibit a somewhat lower gel-to-
liquid phase transition compared with diacylglycerophos-
phoethanolamine [35]. On the other hand measurements of
relative membrane lipid mobility as determined by the
fluorescence anisotropy of diphenylhexatrienyl derivatives in
control cells and cells deficient in plasmalogens revealed a
correlation between fluorescence anisotropy and cellular
plasmalogen content. Hence, the plasmalogen-containing cell
membranes were less fluid than the plasmalogen-deficient
membranes [36].
The abundant appearance of polyunsaturated fatty acids at
the sn-2 position of plasmalogens suggests these phospholipids
to act as a membrane store from where polyunsaturated fatty
acids particularly arachidonic acid might be released through
the activity of a plasmalogen-specific phospholipase A2 [8,37–
39]. However, investigations on the phospholipase A2-mediated
release of arachidonate from control and plasmalogen-deficient
macrophage-like cells did not show any difference in the
kinetics of arachidonic acid release indicating that in vitro data
need to be carefully examined in appropriate in vivo model
systems in order to assess their physiological relevance [8].
2.4. Plasmalogens favor membrane fusion
Plasmenylethanolamines undergo transition from the lamel-
lar liquid crystalline (Lα) phase to the HII inverted hexagonal
phase at distinctly lower temperature than diacyl phosphatidy-
lethanolamines [36,40]. This propensity to form nonlamellar
lipid structures seems to predispose plasmenylethanolamines to
play an important role in physiological processes, such as
balancing between bilayer and non-lamellar phases. Recent
models on protein-free membrane fusion, such as the stalk
hypothesis, relate on the formation of distinct intermediate
stages, including approach of the membranes to small distances
followed by local perturbations of the lipid structure, merger of
proximal monolayers, stalk formation as well as expansion and
final pore formation [41–43]. The low transition temperature of
plasmalogens may particularly facilitate formation of the initial
stages of fusion that seem to be promoted by the intrinsic nature
of the sn-1 vinyl ether chain, as the unsaturation index of the
sn-1 aliphatic chain plays a dominant role in determining the
transition temperature [44,45]. The role of plasmalogens in
membrane fusion is further illuminated by observations that
show high plasmalogen concentrations in subcellular mem-
branes implicated in rapid membrane fusion, e.g. synaptic
vesicles [46]. Direct evidence for a fusogenic activity of
plasmenylethanolamine was obtained by measuring Ca2+-
induced fusion rates of phosphatidylserine liposomes with
liposomes comprised of equimolar mixtures of phosphatidyl-
choline and either plasmenylethanolamine or phosphatidyleth-
anolamine [44,45]. Highest fusion rates were measured with
plasmenylethanolamine liposomes containing arachidonic acid
at the sn-2 position of the glycerol moiety. These data are
particularly interesting, as they attribute to the lipids involved
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implicated in the targeted movements of lipids to and within
membranes might be an important future challenge. Protein-
dependent fusion of membranes requires a complementary set
of SNARE proteins assembling into the trans-SNARE
complex. Thus, SNARE proteins bringing membranes into
close contact are essential determinants for fusion specificity
[47–49]. However, it is still a matter of debate whether
SNAREs are required for later subsequent stages of fusion,
such as for merger of membranes. Although there are data
indicating a role ether lipids may have in membrane fusion in
vitro, their functional implication in vivo remains to be
established.
3. Mouse knockout models with ether lipid deficiency
Two peroxisomal enzymes, DHAPAT and ADAPS, are
essential for the formation of the sn-1 alkylglycerol ether bond
characteristic for all ether lipids [1]. Mutations in these enzymes
or factors involved in their posttranslational import result in
altered cellular levels of ether lipids. The peroxisome biogenesis
disorders, such as ZS or RCDP, are paradigmatic for disorders to
which plasmalogen deficiency significantly contributes
[3,4,50].
3.1. Models exhibiting a Zellweger phenotype
Currently, three Zellweger mouse models were described.
They were based on the targeted deletion of either Pex5, the
peroxisomal targeting signal 1 (PTS1) receptor or Pex2, an
integral peroxisomal membrane protein containing a RING
finger domain and being involved in peroxisomal membrane
protein import or Pex13, a component of the receptor docking
complex [51–53]. Although differences were reported, these
mice show many phenotypes similar to that observed in
Zellweger patients. Pex5 and Pex2 knockout mice are growth-
retarded, severely hypotonic, have a disturbed food intake and
most of them die within 24h after birth. In these mice cellular
abnormalities were found in the central nervous system (CNS),
particularly the cortical plate and the inferior olive indicating
neuronal migration defects to occur [54]. In Pex2 knockout
mice cerebellar alterations, such as a defective foliation
patterning, were accompanied by reduced dendritic arborization
of Purkinje cells [55].
Ultrastructural analysis of Pex5 knockout mice revealed
alterations of mitochondrial morphology predominantly in
hepatocytes [56,57] similar to those described in early reports
of Zellweger patients [58]. The morphological changes in the
inner mitochondrial membrane, such as patterning of cristae,
correlated with functional impairments including decreased
activities of complex I and complex V. These impaired
mitochondrial functions, however, did not affect cellular levels
of ATP. Importantly, no evidence was found indicating
oxidative damage of proteins and lipids and there were no
signs for an elevated oxidative stress response [57]. Docosa-
hexaenoic acid (DHA), a major polyunsaturated fatty acid in
mammalian CNS and retina was reported to be profoundlydeficient in Zellweger patients [59]. When administered daily to
the pregnant Pex5-deficient mother it normalized brain DHA
levels in the offsprings. However, restoration of brain DHA
concentrations had no effect on the pathological abnormalities,
including defects in myelination, visual functions, neuronal
migration and plasmalogen biosynthesis [54].
The third Zellweger mouse model was generated by Cre-
loxP disruption of the Pex13 gene [53]. Pex13p is a pero-
xisomal integral membrane protein involved in both PTS1 and
PTS2 protein import. Together with Pex14 and Pex17, Pex13
forms the docking complex that appeared to be linked via
Pex8 to the RING-finger import complex comprised of Pex2,
Pex10 and Pex12 [60]. Similar to Pex5 and Pex2 knockout
mice, Pex13 knockout mice exhibit many of the clinical fea-
tures observed in ZS. The brain of these mice shows disor-
dered cerebral cortex lamination consistent with a neuronal
migration defect. While visceral organs of these animals were
unremarkable by light microscopy, ultrastructural examination
of the liver revealed abundant large lipid droplets, mitochon-
dria with abnormal morphology of cristae and in kidney a
delayed differentiation of glomeruli including paucity of
podocyte foot processes [53].
The phenotypic similarities in Zellweger patients and in
Pex5-, Pex2-, and Pex13-deficient mice clearly indicates that
these mouse models are useful systems to explore the
pathogenic mechanisms involved in ZS. However, as nearly
all of the peroxisomal functions, including hydrogen peroxide
metabolism, peroxisomal α− and β-oxidation and synthesis of
ether lipids were impaired, a complex phenotype results.
Plasmalogen levels were decreased, however, how and in as
much this contributes to the overall phenotype may be difficult
to establish. In this context the Pex11β-deficient mouse model
is worthwhile to be mentioned, as Pex11β-deficient mice
display several congenital anomalies shared by ZS, such as
developmental delay, hypotonia, neuronal migration defects,
enhanced neuronal apoptosis and neonatal lethality. However,
these mice do not exhibit defects in peroxisomal protein import
and alterations in mitochondrial structure [61] and are
characterized by only partial defects in peroxisomal fatty acid
β-oxidation and ether lipid biosynthesis. Therefore, it was
suggested that accumulation of peroxisomal substrates or lack
of peroxisomal products might not account for the symptoms
caused by Pex11β deficiency. Due to the absence of severe
metabolic disturbances, altered physical properties of the
peroxisomal membrane affecting different metabolite transpor-
ters were proposed to activate or inactivate one or more
signaling pathways including the nuclear hormone receptors
RXR, PPARα and PPARγ [62].
3.2. The Pex7 knockout mouse model
ADAPS, the second enzyme implicated in ether bond
formation is imported into peroxisomes via the PTS2 pathway
involving Pex7, the PTS2 receptor [63]. Thus, genetic defects in
Pex7 result in cytosolic mislocalization and proteolytic
degradation of ADAPS and consequently generate RCDP
type 1, a distinct human autosomal recessive peroxisomal
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[4,64]. Biochemically, RCDP patients show a severe depletion
of plasmalogens and additionally impaired α-oxidation of
phytanic acid and β-oxidation of very-long-chain fatty acids. A
similar phenotype is observed in Pex7 knockout mice that are
born with severe hypotonia and growth retardation. Although
most animals die during the perinatal period, some survive even
beyond 18 months. The brain of these mice displayed defects in
neuronal migration. However, the abnormalities seen in the
Pex7-deleted animals were less pronounced than those in the
Pex5 knockouts [2]. In addition to brain abnormalities, Pex7
knockout mice revealed a delayed endochondral ossification.
Defects were described in the skull, the inner ear and the axial
and appendicular skeleton. Histological examination of the
femurs further revealed reduced mineralization. In cultured
fibroblasts of the Pex7 knockouts plasmalogen biosynthesis was
drastically reduced by 85–90% and a marked reduction in the
level of plasmalogens in fibroblasts, erythrocytes and brain was
noted. These alterations in plasmalogens were accompanied by
an about 60% decrease in the activity of C26:0 and pristanic
acid β-oxidation and an impairment of phytanic acid degrada-
tion by peroxisomal α-oxidation [2]. Thus, Pex7 knockout mice
closely mimic human RCDP type 1 and represent a suitable
model to study the defects particularly those in endochondral
ossification on a molecular level.
3.3. Niemann–Pick type C disease, Down syndrome and
Alzheimer’s disease are distinguished by altered
concentrations of plasmalogens
In addition to ZS and RCDP a number of other disorders
are known that also are connected to altered concentrations of
plasmalogens. These disorders include Niemann–Pick type C
(NPC) disease, Down syndrome (DS) and Alzheimer’s
disease (AD). NPC is a rare neurovisceral disorder charac-
terized by progressive hepatomegaly and CNS neurodegen-
eration [65]. The disease is further distinguished by the
accumulation of free cholesterol, sphingolipids and other
lipids within the endosomal/lysosomal compartment, a
phenotype that is also observed in human and mouse skin
fibroblasts (SFs) with isolated ether lipid deficiency
[50,66,67]. NPC is caused by mutations in either the NPC1
or NPC2 protein, though NPC1 mutations account for 95% of
the reported NPC cases. NPC1 encodes a glycoprotein of
170–190kDa with 13 putative transmembrane spans including
a conserved sterol-sensing domain. NPC2, on the other hand,
is a soluble lysosomal protein with high affinity cholesterol
binding and lower affinity fatty acid binding [68]. The
functions of NPC1 and NPC2 are not clear yet. In cells
lacking a functional NPC1 gene transport of cholesterol from
late endosomes to various intracellular destinations including
the plasma membrane is severely disturbed [69] and in
addition esterification of low density lipoprotein cholesterol is
impaired [70,71]. The findings that production of 25-
hydroxycholestrol and 27-hydroxycholesterol is reduced in
NPC fibroblasts in response to LDL cholesterol indicate a
role the NPC proteins play in channeling excess LDLcholesterol to intracellular sites of oxysterol synthesis [72].
Cholesterol overload in NPC1 and NPC2 mutants, thus,
results from a failure to both suppress sterol regulatory
element-binding protein-dependent gene expression and
activate liver X receptor functions. The defects in cholesterol
trafficking observed in all cell types may predominantly affect
neurons. NPC1 was found in recycling endosomes of
presynaptic nerve terminals, a topology suggesting NPC1 to
play a role in the endosomal pathway of synaptic vesicle
recycling [65,67].
Plasmalogens might be essential for distinct steps in choles-
terol transport. Evidence for this is derived from observations
demonstrating reduced plasmalogen concentrations in the brain
of NPC mice and accumulation of free cholesterol in an
endosomal/lysosomal compartment of SF with isolated plasma-
logen deficiency [50,73]. Moreover, plasmalogen-deficient
CHO cells show a significantly reduced activity in LDL-
stimulated cholesterol esterification by acyl-CoA cholesterol
acyltransferase in the ER [74]. Although the mechanisms by
which plasmalogens interfere with intracellular cholesterol
movements are not clear yet, the data obtained so far indicate
a requirement of plasmalogens for cholesterol trafficking from
both plasma membrane and lysosomes to the ER.
Post mortem analyses of phospholipids in the brain of AD
patients revealed a significant and selective deficiency of
plasmenylethanolamine that was more pronounced in the
hippocampus, in mid-temporal and frontal cortex, regions
known to be more seriously affected in AD than the caudate
nucleus, substantia nigra and cerebellum [75–77]. No
alterations in plasmalogen content were seen in cerebral
white matter [76]. A more recent study investigated by ESI-
MS post mortem brain tissue lipid extracts of AD patients that
were correlated to known clinical dementia ratings (CDR)
[78]. Plasmalogen content was determined in four different
brain regions, frontal, temporal and parietal cortex as well as
cerebellum. The ESI-MS analyses showed (i) significant
plasmalogen deficiency of up to 40mol% of total plasmalogen
in white matter from all brain regions examined at an early
stage of AD (CDR 0.5), (ii) plasmalogen deficiency in gray
matter from all cerebral regions studied and correlating with
CDRs, and (iii) normal plasmalogen levels as expected in
cerebellar gray matter at all examined CDRs. Moreover,
reduced concentrations of plasmalogens of up to 10mol% of
total plasmenylethanolamine were also observed in two AD
transgenic mouse models, APPV717F and APPsw [46]. Plasma-
logen deficiency was noted in cerebral cortex, but was also
absent in cerebellum. However, sulfatides, a class of myelin-
specific sphingolipids, were depleted by up to 93% in gray
matter and by up to 58% in white matter of all human brain
regions examined [79]. In contrast, the content of ceramide,
potential sulfatide hydrolysis products, was elevated more than
3-fold in white but not gray matter and peaked at the stage of
very mild dementia (CDR 0.5). Similarly, the marked decrease
in sulfatides already occurred in the earliest stages of clinically
identifiable AD, i.e. at CDR 0.5.
In interpreting these data one major question arises. Is
plasmalogen deficiency a primary cause for AD or rather does it
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obtained from the AD transgenic mouse models indicating
plasmalogen deficiency most likely to be caused by the
accumulation of abnormal β amyloid (Aβ) peptide species, it
was suggested that plasmalogen deficiency might not be the
initial cause of AD and other factors additional to Aβ
accumulation might favor progression of the disease. This
view may be further supported by the fact that absence in these
AD mouse models of apoE that also participates in AD
pathogenesis [80], prevents both Aβ deposition and plasmalo-
gen deficiency [81]. ApoE is a 299 amino acid glycoprotein. It
is the major protein of VLDL and the major apolipoprotein in
brain. The identification of the ε4 variant of apoE as a risk factor
for late-onset AD indicates cholesterol to play a direct role in
AD pathogenesis [82,83]. As on the one hand plasmalogen
deficiency affects intracellular cholesterol distribution and on
the other hand impaired cholesterol homeostasis strongly favors
AD pathogenesis, brain plasmalogens may be linked to AD by
their effects on cholesterol [10,50,74].
Another aspect relates to the antioxidative capacity of
plasmalogens mentioned above. There is some evidence for an
increased oxidative brain damage in AD. Several factors
including mitochondrial dysfunction, glutamatergic neurotrans-
mission and Aβ accumulation were proposed to contribute to it
[84,85]. In particular, Aβ accumulation seems to produce
enhanced oxidative stress by inducing both protein and lipid
peroxidation [86–88]. Although an attractive hypothesis, the
antioxidative character of plasmalogens in vivo remains to be
established.
The existence of a link between brain plasmalogens and
AD is also suggested by studies of DS patients. The
prevalence of dementia in patients between 50 and 59years
of age is about 55% and in those over 60years of age it is 75%
[89]. In adult patients loss of neurons is dramatic and
neurofibrillary tangles and neurite Aβ plaques are prominent
[90]. The reason for these neuropathological findings may
implicate triplication of both the APP gene and the beta-site
amyloid precursor protein cleaving enzyme (BACE) 2 gene
that both are located on chromosome 21 [91,92]. Accordingly,
BACE-2 protein and plasma Aβ levels of DS patients were
significantly increased compared with controls [93–95].
Furthermore, the lifelong increase in ROS caused by
mitochondrial dysfunction also may affect abnormal APP
processing [96]. Superoxide dismutase (SOD) having anti-
oxidative properties is also present on chromosome 21 and is
found in higher activity in the fetal brain of DS patients.
Although deactivating superoxide, SOD may led to higher
concentrations of hydrogen peroxide and hence may contrib-
ute to enhanced oxidative stress [97]. In this context it may be
worthwhile to mention that post mortem analyses of brain
phospholipids in DS patients between 38 and 68years of age
showed a significant decrease in the concentrations of
phosphatidylinositol and plasmenylethanolamine in frontal
cortex and cerebellar gray matter by 37% and 35%,
respectively [98]. The cholesterol/phospholipid ratios, howev-
er, were not significantly changed indicating compensatory
mechanisms to maintain these ratios.4. The DHAPAT-deficient mouse model
4.1. Isolated plasmalogen deficiency causes defects in CNS
myelination
Initiation of axon myelination requires association between
myelin-forming glia and the axon to be ensheathed. This
process involves the formation of a large cell–cell adhesion
complex comprising the paranodal axo-glial junction [99,100].
Its formation is the result of complex intra- and intercellular
activities providing the targeted delivery of key molecules to the
nodal domain. Two other processes following assembly of the
nodes of Ranvier are related to the regulation of myelin
thickness and the longitudinal extension of myelin segments in
response to axon lengthening [100]. Once the nodal proteins
arrived at the nascent node, they might recruit other proteins to
complete the nodal architecture. Selection of axons and
initiation of axo-glial contacts might involve cell adhesion
molecules, such as NCAM and L1, integrins for oligodendro-
cyte sensing of axonal molecules, laminins, the ligands for some
integrins and neuregulins, neuronal effector molecules influ-
encing glial cells to myelinate [101–104]. Although most of the
cell–cell interactions were controlled by proteins, lipid raft
microdomains (LRMs) might be a way cells deliver lipid–
protein complexes to distinct destinations in the plasma
membrane. The cell–cell interactions are required for the
formation of tissue-specific junctional complexes prerequisite
to functional synchronization.
Compared with plasma membranes of other somatic cells the
myelin membrane contains particularly high concentrations of
cholesterol, galactolipids and plasmalogens [6,8]. Mice lacking
the ability to synthesize cholesterol in the oligodendrocyte show
a delay in myelination, a defect that, however, might be at least
partially compensated for by enhanced cholesterol uptake [105].
Furthermore, mice that cannot synthesize galactolipids show
myelin defects in the CNS, including disrupted axo-glial
junctions and paranodes [106,107]. Thus, cholesterol and
glycosphingolipids are essential constituents of myelin raising
the question as to their proposed function. Central to
myelinogenesis is the assembly of the myelinating process to
the axonal plasma membrane and its extension during axon
growth. How this might be accomplished is not clear yet,
however, the concept of LRMs might offer an explanation for
the underlying mechanism. LRMs are membrane microdomains
enriched in cholesterol and glycosphingolipids and often serve
as platforms that are able to accumulate distinct proteins
particularly those that are bound to membranes by a GPI-anchor
[108–111]. These protein–lipid complexes were already
assembled in the ER and subsequently targeted to the growing
plasma membrane representing sites of adhesion to terminal
loops of myelin creating juxtaparanodal and paranodal areas
[112]. The junctional complexes determining these nodal zones
are essential for the correct topology of the nodal ion channels.
Recent studies on factors inhibitory to neurite outgrowth
identified oligodendrocyte myelin glycoprotein (OMgp). In rat
spinal cord, OMgp was localized to distinct oligodendrocyte-
like cells whose processes converged at the node. Since OMgp
Fig. 2. Semithin cross-sections of the orbital, myelinated portion of the optic
nerve showing a significant reduction in the number of large axon profiles in the
adult DHAPAT knockout mouse (−/−) compared with the control (+/+). Scale
bar, 10μm.
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that it might function in suppressing collateral sprouting [113].
Similarly, in rat optic nerve NG2 expressing oligodendrocyte
precursor-like cells have been proposed to tightly ensheath the
nodal axon, thus preventing axonal sprouting [113,114]. NG2
positive cells are abundantly expressed in the adult CNS and
NG2 proteoglycans have also been shown to inhibit neurite
outgrowth [115]. Future aspects, therefore, might also consider
the plasmalogen content of heterogeneous oligodendrocyte-like
glial cell populations and the role plasmalogens play in the
process of nodal ensheathment.
The concept that ether lipids might play a role in building up
the nodal architecture is supported by several observations. (i)
Plasmalogens are the dominating glycerophosphoethanolamine
species in LRMs isolated from myelin [10], (ii) plasmalogens
were found to accumulate in LRMs isolated by a non-detergent
technique [116], (iii) seminolipid (SGalAAG) is enriched in
Triton X-100-isolated LRMs of sperm cell membranes [117],
(iv) anti-tumor ether lipids, such as edelfosine (1-O-octadecyl-2-
O-methyl-sn-glycerophosphocholine) and miltefosine (1-hexa-
decylphosphocholine), although by themselves do not form
sterol-rich domains in fluid model membranes, stabilized
palmitoyl-sphingomyelin/cholesterol-rich domains against tem-
perature-induced melting suggesting that they affect LRMs, (v)
many GPI-anchored proteins, although not thoroughly analyzed
yet, contain in their lipid anchor a 1-alkyl-2-acylglycerol moiety
(see Section 2.1) the synthesis of which should require
functional peroxisomes [108,118] and (vi) plasmalogen levels
increase in concentration in parallel to myelination in human
cerebrum, cerebellum and brain stem [119]. Finally, the optic
nerve and the corpus callosum of plasmalogen-deficient
knockout mice show distinct hypomyelination (Fig. 2A and B)
and nerve conductivity measured in the corpus callosum was
significantly reduced (Teigler et al., unpublished). Thus, lack of
plasmalogens that in myelin account for about 80% of total
myelin glycerophosphoethanolamines [46] has both structural
and functional consequences for the myelinated axon.
4.2. Ether lipids in male reproduction
Cells of the non-stem germ cell lineage in testis synthesize
ether phospholipids including seminolipid at unusually high
concentrations. Although much has been learned within the last
years, the physiological role these lipids play in male
reproduction is not known. In this section new data on
plasmalogens and seminolipid are summarized based on the
structural alterations in testis of the ether lipid-deficient
DHAPAT knockout mouse and the phenotypes seen in related
mouse models. Main emphasis is the impact of ether lipid
deficiency on germ cell and somatic cell maturation, cell cycle
synchronization and progression of spermiogenesis in the
mouse seminiferous epithelium.
4.2.1. Ether phospholipids in spermatozoa
Spermatozoa are unique among mammalian cells in that
they contain high levels of ether- linked phospholipids fre-
quently carrying polyunsaturated fatty acid chains at the sn-2position of the glycerol moiety. In sperm plasma membranes
approximately 2/3 of both phosphocholine and phosphoetha-
nolamine glycerolipids are ether-linked and contain aliphatic
alkyl and alkenyl chains, whereas diacyl species account for
about 30% [120,121]. The alkyl chains at the sn-1 position are
almost exclusively comprised of C16:0 and the fatty acid
bound at the sn-2 position is polyunsaturated, such as in
docosapentaenoic acid or DHA. As a consequence of specific
lipid remodelling during sperm epididymal maturation a
relative increase in plasmalogens in sperm plasma membranes
was observed. This increase was accompanied by enhanced
levels of C22:5 and C22:6 and reduced concentrations of
C18:1 and C20:4 most likely prerequisite for the fertilizing
capacity of spermatozoa acquired during epididymal transit
[121–125]. Considering the high concentration of ether
phospholipids in the germ cell membrane and the metabolic
stability of the ether linkage, ether lipids were suggested to
contribute to both the formation of macro- and microdomains
required for spermatogenesis and the compartmentalization of
the highly polarized sperm membrane, including the head
and its subdomains, the midpiece and the flagellum. Further-
more, these ether lipids might be responsible for mainte-
nance of the sperm’s fertilizing competence during passage
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tion [123,125].
4.2.2. Synthesis and functional role of seminolipid in testis and
spermatozoa
As mentioned above (Fig. 1), seminolipid (SGalAAG) is the
major sulfogalactolipid in differentiating mammalian sperma-
tocytes and spermatozoa accounting for 5–8mol% of total
lipids and more than 90% of the total glycolipids in mature
gametes. As a minor component (0.2mol%), SGalAAG was
also found in white matter of the adult mammalian brain, but
seems to be absent from most somatic cells underlining its
crucial role in spermatogenesis and fertilization. In testis, more
than 95% of SGalAAG contain hexadecanol ether-linked to the
sn-1-position and hexadecanoic acid esterified to the sn-2-
position [15,122,126,127]. The molecule is inserted into the
outer leaflet of the sperm plasma membrane. Using an anti-
sulfogalactolipid antibody, SGalAAG was exclusively detected
in the germ cell lineage of the adult mouse testis decorating the
plasma membranes of differentiating type B spermatogonia,
spermatocytes, spermatids, and spermatozoa [128].
SGalAAG and sulfatide contain the same sulfated galactose
head group, and the last steps of synthesis of both were
catalyzed by the sequential activities of UDP-galactose:
ceramide galactosyltransferase (CGT) located in the ER and
cerebroside sulfotransferase (CST) present in Golgi membranes
[129,130]. SGalAAG synthesis is developmentally regulated
and initiated in the mouse testis at P8. Whereas a strong focal
patterning of seminolipid was reported at the initiation of
meiosis at P10–P12 [128,131], all seminiferous tubules were
intensely immunostained at P14–P18 coinciding with (i)
SGalAAG concentration peak at around P17, (ii) entrance of
germ cells into the pachytene stage, (iii) their transit to the
abluminal compartment of the seminiferous epithelium, and (iv)
functional maturation of Sertoli cells forming tight junction
complexes that constitute the blood–testis-barrier. The bulk of
SGalAAG is synthesized in late zygotene and early pachytene
spermatocytes [15,126,128,129]. In rat testis it was shown that
the activity in pachytene spermatocytes is tightly controlled and
restricted to a 3-day period of the entire 55-day spermatogenic
cycle [132].
The sulphated galactose moiety of SGalAAG is preserved
throughout spermatogenesis, sperm maturation, and initial in
vitro sperm capacitation [133,134]. Using confocal fluorescence
microscopy the majority of SGalAAG was found in LRMs
localized in a globular pattern to the apical subdomain of the
sperm head [117], the expected site of sperm recruitment to the
egg coat [122,135,136]. Interestingly, after in vitro capacitation
or sperm binding to zona pellucida-coated coverslips SGalAAG
relocalized from the apical ridge domain to the equatorial
subdomain of the sperm surface. This reorganization occurs
prior to the acrosome reaction and concentrates SGalAAG at the
predestined site implicated in lateral egg binding and subse-
quent fertilizing fusion [122,137]. These studies paradigmati-
cally indicate the involvement in the dynamics of sperm head
polarity of SGalAAG and its requirement for cell–cell and cell–
extracellular matrix interactions leading to fusion.4.2.3. Arrest of spermatogenesis in ether lipid-deficient mice
Disruption of the DHAPAT gene in mice causes infertility
and arrest of the spermatogenic cycle between late pachytene
and the spermatid stage. Seminiferous tubules are completely
devoid of elongated spermatids and mature spermatozoa
indicating complete block of normal spermiogenesis and
azoospermia (Fig. 3). Depletion of germ cells, predominantly
primary and secondary spermatocytes, and marked Sertoli cell
vacuolization were additional signs of a disturbed synchroni-
zation of the germ cell cycle. There is a gradual loss of
intercellular bridges stabilizing the clonal syncytia of sperma-
tocytes leading to formation of multinucleated giant cells, the
majority of which has completed meiosis (Fig. 3C). In testes of
older animals numerous tubules displayed the phenotype of
partial or complete Sertoli cell-only syndrome indicating
gradual loss of spermatogonia also to occur.
These observations provided first experimental evidence for
the essential role ether phospholipids and seminolipid play in
spermatogenesis. Ether lipids might be less important for the
amplification of stem cells and the differentiation of spermato-
gonia in the abluminal compartment of the seminiferous
epithelium and might not be required for completion of meiotic
karyokinesis (Fig. 3B and C). They are, however, critical
determinants for (i) the transit along somatic Sertoli cells of
syncytial late pachytene germ cells to the correct adluminal
compartment thereby mediating specific cellular junctions, (ii)
the final steps of spermatid cytodifferentiation, and (iii)
establishing and maintaining the integrity of stable intercellular
bridges constituting syncytial clones of adluminal spermato-
cytes and spermatids. Both complex Sertoli cell–spermatid
junctions and stable intercellular bridges are essential for
maintenance of spermiogenesis and regulated spermiation
[138–140]. The intercellular bridges represent highly special-
ized plasma membrane regions stabilized by an actin filament
complex. Disruption of the actin ring by cytochalasin D resulted
in formation of multinucleated spermatids and spermatogenic
arrest [141] similar to the DHAPAT knockout phenotype.
Spermatogenesis in CST knockout mice lacking the sulfo-
galactolipids, sulfatide and seminolipid progresses through
spermatogonial amplification and differentiation, but is arrested
at late pachytene stage before completion of the first meiotic
division [130]. A similar phenotype has been described in CGT
knockout mice [129]. In DHAPAT knockout mice, however, the
majority of syncytial germ cell clones completed meiotic
karyogenesis I and II and most likely reached the stage of
multinucleated spermatids. Thus, in CST and CGT knockout
mice accumulation of precursors of sulfogalactolipid synthesis
seemed to be more detrimental to the meiotic program than the
complete absence of ether lipids in DHAPAT knockout mice.
However, detailed studies on gene expression as well as lipid and
immunocytochemical analyses are required to precisely deter-
mine the block in germ cell development and to delineate the
functionality of Sertoli cells in ether lipid-deficient mice.
Searching for mutant mouse strains impaired in spermioge-
nesis and exhibiting the phenotype of multinucleated spermatids
similar to that seen in DHAPAT knockout mice revealed a
number of specific candidate genes. Interestingly, one of these
Fig. 3. Semithin sections of wt (A) and DAPAT knockout (B, C) testes. In the
first wave of spermatogenesis the multilayered seminiferous epithelium of a 30-
day-old wt-mouse contains the germ cell set typical for stage VI of the
spermatogenic cycle [169,170]; spermatogonia (1), midpachytene spermato-
cytes (2) and round spermatids in the initial phase of acrosome formation (3,
arrowhead). The seminiferous epithelium of 6months old DHAPAT knockout
mice is strikingly disorganized and elongated spermatids typical for stage VI of
adult testis epithelium are completely absent. Opening of intercellular bridges
(B, arrows) and the initial development of multinucleated spermatid cells (B)
exhibiting initial acrosome formation (C, arrowheads) are seen. In 6-month-old
mutant mice elongated spermatids corresponding to stage VI are completely
absent. S=Sertoli cell, methylene-azur II stain. Scale bar, 100μm.
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of which causes infertility by loss of a unique subset of neutral
fucosylated glycosphingolipids (FGSLs) [142]. None of these
polyunsaturated FGSLs exclusively synthesized in germ cells
floated up with detergent-insoluble lipid rafts suggesting that the
germ cell membrane contains functionally distinct glyco-
sphingolipid domains required for the spermatid differentiation
program. At this checkpoint lack of major lipid constituents,such as plasmalogens, seminolipid and FGSLs seems to initiate
disruption of the domain structure and breakdown of the actin
cytoskeleton leading to multinucleated spermatids and apoptosis
of the germ cell syncytium. Maintenance of membrane domains
appears to be under the paracrine control of mature Sertoli cells.
Recent data demonstrate that in the absence of Sertoli cells
spermatogonia proliferate and differentiate to spermatocytes and
round haploid spermatids. However, stem cell factor, a secretion
product of Sertoli cells, could not induce sperm tail elongation
and generation of intercellular bridges [143].
Another important aspect relates to the androgen receptor
present in functionally mature Sertoli cells, but not germ cells.
Androgen receptor expression is developmentally regulated
and asynchronous progression of spermatogenesis and block
in spermiogenesis, as observed in the ether lipid-deficient
mouse, may well reflect disturbance in the androgen-
dependent cross talk between germ cells and the somatic
compartment of the seminiferous epithelium caused by
impaired Sertoli cell maturation.
The present results on the role of ether lipids in spermio-
genesis were mainly obtained by structural and immunocyto-
chemical analysis of the ether lipid-deficient testis. Determining
as close as possible the time point of the spermatogenic arrest it
appeared that ether lipids developmentally regulate in a stage-
specific manner the organization and distinct compartmental-
ization of the plasma membrane crucial for the integrity and
maintenance of the clonal spermatid syncytium and the
progression of spermiogenesis.
4.3. Role of ether lipids in lens organization and transparency
The avascular lens is built up by a single cell type forming
two compartments, the anterior epithelium and the highly
differentiated fiber cell mass both surrounded by a specialized
basement membrane, the lens capsule. Maintenance of lens
organization and transparency requires synchronized interac-
tions between the capsular extracellular matrix and the lens
epithelial cell membrane as well as gap junction-mediated
intercellular communication that both guarantee life-long
coordinated cell proliferation, differentiation and precisely
ordered apposition of lens fibers to the lens core [144].
Plasmalogens, in particular plasmenylethanolamines, have been
identified as major lens phospholipids in several mammalian
species including mice and humans [145–150], and DHAPAT
knockout mice exhibit early postnatal bilateral cataractogenesis
[9,10]. Thus, the lens represents a valuable model system to
define the putative functions plasmalogens play in epithelial cell
polarity, cell migration and differentiation as well as in integrity
of cell–cell and cell–matrix adhesions.
4.3.1. Ether lipids of the lens
The relative amounts of plasmalogens and sphingomyelins
vary in different regions of the mammalian lens. Plasmeny-
lethanolamines are enriched in the epithelial cell layer and are
most abundant in the outer cortical zone, but significantly
decrease toward the center of the lens indicating maximal
synthesis of plasmalogens during lens fiber differentiation and
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the inner cortical zone and in lens nuclear fibers [151].
Correspondingly, enzymatic activities of both DHAPAT and
ADAPS are 7-fold higher in cultured lens epithelial cells than in
lens homogenates. Both enzymes co-localize with catalase in
peroxisomes [150] that are particularly abundant in differenti-
ating lens epithelial cells and elongating fiber cells. Interestingly,
peak levels of HMG-CoA reductase have been demonstrated in
the outer cortical lens region (outer 5% of the lens radius)
indicating maximal cholesterol synthesis during fiber elongation
[152]. In the avascular lens both endogenous ether lipid and
cholesterol biosynthesis are crucial for developmental fiber
elongation as an estimated 1000-fold increase in lens fiber
plasma membranes has to be guaranteed. In addition, a steep
gradient of the molar cholesterol to phospholipid ratio ranging
from 0.8 in lens epithelium to 3.5 in the nucleus is maintained in
lens cell membranes [153,154]. Gap junctions playing an
important role in cell–cell coupling required for maintenance
of overall lens transparency, were found to be highly enriched in
cholesterol. In the chicken lens, for example, gap junctions
exhibiting a ratio of cholesterol to phospholipid of 3.1, contain
about 57% of total fiber cholesterol [155].
4.3.2. Plasmalogen deficiency causes cataract
DHAPAT deficiency causes a number of distinct develop-
mental eye defects including microphthalmia, dysgenesis of the
anterior eye chamber, persistence of the hyaloid artery,
(Bergmeister papilla), and optic nerve hypoplasia. The most
conspicuous anomalies, however, affect the adult lens display-
ing bilateral cataract, keratolenticular adhesion and formation ofFig. 4. Major structural alterations in the lens of the DHAPAT knockout mouse. In co
cell monolayer resulting in loss of epithelial cell polarity, altered architecture of the le
lenticonus anterior (B). Epithelial cell layers (arrowheads), lens fiber swelling and cl
cell–cell and cell–matrix interactions as well as altered fiber cell migration and elona lenticonus anterior (Fig. 4A and B). Detailed histological
analysis of the ether lipid-deficient lens revealed (i) focal
disruption of the anterior monolayer of lens epithelial cells and
invasion of unpolarized epithelial cells into the thickened lens
capsule, (ii) loss of cell–cell adhesion sites resulting in massive
vacuolization and abnormal layering of secondary fiber cells in
the outer cortical zone and (iii) aggregation at the bow area of
poorly differentiated epithelial cells extending as a multilayered
sheath toward the disorganized and frequently vascularized
posterior suture [10]. These data indicate plasmalogens to be
essential for postnatal lens growth, integrity of cell–cell and
cell–matrix interactions, anterior lens epithelial cell polarity and
barrier function and maintenance of metabolic homeostasis and
lens transparency. Under normal conditions postmitotic fiber
cells at the equatorial region elongate by migration of their
leading edges both along the epithelium and the capsule to reach
the anterior and posterior suture, respectively. As in ether lipid-
deficient mice lens epithelial cells continue to migrate to the
posterior pole (Fig. 4C), plasmalogens may specifically
contribute to the control of migration and elongation of lens
cortical fiber cells.
Cataract similar in phenotype to that observed in the plas-
malogen-deficient lens is also generated by disrupting genes
involved in cell–cell and cell–matrix adhesion, cell migration
and gap junction-mediated cell–cell coupling [156–161]. The
related proteins are frequently GPI-anchored and sort to LRMs.
Therefore, it is interesting that human inborn defects in cho-
lesterol biosynthesis, such as X-linked dominant chondrodys-
plasia punctata (Conradi–Hunermann–Happle syndrome),
mevalonic aciduria, lathosterolosis, Smith–Lemli–Opitz syndromentrast to controls (A) the adult mutant lens shows disruption of the lens epithelial
ns capsule (arrow), disorganization of the anterior suture and the formation of a
efts at the posterior suture (star in panel C) point to the overall severe defects in
gation in the cataractous lens. Scale bar, 50μm.
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associated with development of cataract [153,162–166]. Thus,
it is tempting to speculate that both lens plasmalogens and
cholesterol are involved in the formation of distinct plasma
membrane domains required for regulated postnatal lens
growth. The importance of plasmalogens for the human lens
is further documented by phospholipid analyses indicating
plasmalogens and plasmalogen-related species to decrease
dramatically with age and formation of cataract suggesting
their essential role in cataractogenesis [148].
5. Conclusions
Previous studies attributed to ether lipids a number of
functions, including regulation of membrane fluidity, antiox-
idative capacity, facilitating membrane fusion and storage and
release of polyunsaturated fatty acids. Most of these functions
have been established using in vitro systems. Only few studies
relate on the use of cultured cell lines and important aspects of
plasmalogen functions particularly those related to human
disorders have not been confirmed in animal models. The recent
generation of an ether lipid-deficient mouse model now offers
the possibility to answer questions on the in vivo functions of
plasmalogens. For that reason this review briefly described
previously established functions and focused on major pheno-
types seen in three different tissues of the DHAPAT knockout
mouse: testis, lens and brain. Lack of ether lipids in these tissues
causes early arrest of spermatogenesis between late pachytene
and the spermatid stage, formation of a lenticonus anterior
accompanied with the generation of cataract and hypomyelina-
tion in distinct regions of the CNS. There are several crucial
biochemical and cell biological steps that might be common to
spermatogenesis, lens development and CNS myelination and
whose impairment might lead to phenotypes caused by
plasmalogen deficiency. In all three tissues cell–cell and/or
cell–extracellular matrix interactions play a tremendously
important role in tissue developmental processes. Many of the
junctional proteins involved are GPI-anchored and sorted to
LRMs representing platforms enabling concentration of junc-
tional, signaling and exo-/endocytotic activities. Lack of
plasmalogens might interfere 2-fold with LRM functions.
First, by actively sorting to LRMs and second by affecting the
intracellular distribution and homeostasis of cholesterol that by
itself is an important LRM constituent.
Lack of data from whole animal experiments on the
antioxidative activity of plasmalogens might require alternative
and/or additional interpretations of the role of plasmalogens in
their interaction with ROS. Recent work on peroxisome
proliferator-activated receptor (PPAR) γ revealed two main
groups of natural ligands, fatty acids and phospholipids. Among
the phospholipids both oxidized (hexadecyl azelaoyl phospha-
tidylcholine) and metabolically converted (1-octadecenyl-2-
hydroxy-glycerophosphate) ether lipid species identified were
able to activate PPARγ-dependent cellular responses [167,168].
Thus, future studies might consider products of metabolic
degradation or oxidation of plasmalogens to elicit cellular
responses by nuclear signaling.Acknowledgements
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